Clinical trial
Nitrocamptothecin in Treating Patients With Recurrent or Metastatic Ovarian…
NCT00006267 · Gynecologic Oncology Group, Other · Withdrawn
Key facts
| NCT number | NCT00006267 |
|---|---|
| Title | Nitrocamptothecin in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer |
| Official title | A Phase II Evaluation Of 9-Nitro-Camptothecin In The Third-Line Treatment Of Recurrent Ovarian Or Primary Peritoneal Cancer |
| Lead sponsor | Gynecologic Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Primary Peritoneal Cavity Cancer |
| Intervention type | Drug |
| Interventions | rubitecan |
| Enrollment | 0 |
| Primary completion | May 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 9, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: